Rivaroxaban: all 303 studies that test it
Page 3 of 4. Open to participants first (60), then studies with results posted, then the rest; newest registration first within each.
- Rivaroxaban vs Warfarin in Patients With Metallic ProsthesisTerminatedNCT03566303Phase 2/3
- Rivaroxaban as Thrombosis Prophylaxis in Bariatric SurgeryCompletedNCT03522259Phase 2
- Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)Status unknownNCT03490994Phase 4
- Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple MyelomaActive, not recruitingNCT03428373Phase 2/3
- Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary SyndromeCompletedNCT03363035Phase 4
- The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary InterventionCompletedNCT03331484Phase 3
- Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer PatientsCompletedNCT03282643Phase 1/2
- Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPDStatus unknownNCT03277001Not applicable
- Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage ClosureCompletedNCT03273322Phase 2/3
- Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCVCompletedNCT03201367Not applicable
- Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated CirrhosisStatus unknownNCT03193502Phase 3
- Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous ThrombosisStatus unknownNCT03191305Not applicable
- Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral AnticoagulantsCompletedNCT03181386Phase 3
- Study of Rivaroxaban for CeREbral Venous ThrombosisCompletedNCT03178864Phase 2
- Start or STop Anticoagulants Randomised Trial (SoSTART)CompletedNCT03153150Phase 3
- Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded TrialCompletedNCT03148457Not applicable
- A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous ThromboembolismStatus unknownNCT03139487Phase 2
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)Active, not recruitingNCT03129555Phase 4
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial FibrillationActive, not recruitingNCT03129490Phase 4
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet AlfaCompletedNCT03083704Phase 1
- Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)CompletedNCT03071380Phase 1
- Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.CompletedNCT03055026Phase 3
- Anticoagulation for Advanced Cirrhotic Patients After TIPSStatus unknownNCT03005444Not applicable
- Rivaroxaban or Aspirin for Biological Aortic ProsthesisStatus unknownNCT02974920Phase 4
- Absorption of Rivaroxaban in Patients With Cervical Spinal Cord InjuryWithdrawnNCT02970773Phase 4
- ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)CompletedNCT02935855Phase 4
- Rivaroxaban for Patients With Antiphospholipid SyndromeCompletedNCT02926170Phase 3
- PK of Rivaroxaban in Bariatric Patients - ExtensionCompletedNCT02832947Phase 1
- INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-InferiorityCompletedNCT02832544Phase 3
- INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, SuperiorityWithdrawnNCT02832531Phase 3
- Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee ReplacementCompletedNCT02810704Phase 4
- Cancer Associated Thrombosis, a Pilot Treatment Study Using RivaroxabanCompletedNCT02746185Phase 3
- COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome TrialsWithdrawnNCT02723981Phase 4
- Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.Status unknownNCT02704598Not applicable
- Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial FibrillationStatus unknownNCT02666157Phase 4
- Venous Thromboembolism in Renally Impaired Patients and Direct Oral AnticoagulantsTerminatedNCT02664155Phase 3
- Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy SubjectsCompletedNCT02657512Phase 1
- Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With CirrhosisStatus unknownNCT02643212Phase 3
- Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease StudyStatus unknownNCT02642419Phase 4
- Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort StudyStatus unknownNCT02627053Phase 3
- Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis PatientsCompletedNCT02610933Phase 4
- Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer PatientsTerminatedNCT02583191Phase 3
- Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.CompletedNCT02555111Phase 3
- Pleotropic Effect of New Oral AnticoagulantsStatus unknownNCT02544932Phase 3
- Bioequivalence Study of RivaroxabanCompletedNCT02537457Phase 1
- Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsCompletedNCT02537405Phase 1
- Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule StudyCompletedNCT02486445Phase 3
- Rivaroxaban in Bariatric SurgeryCompletedNCT02438098Phase 1
- PROphylaxis in NOn Major Orthopaedic SurgeryTerminatedNCT02401594Phase 3
- Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AFTerminatedNCT02387229Phase 3
- Prophylaxis of Deep Vein Thrombosis Following Total Hip ArthroplastyCompletedNCT02379663Phase 4
- Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting ConditionsCompletedNCT02367027Phase 1
- Anti-inflammatory Effects of Rivaroxaban Versus DabigatranStatus unknownNCT02331602Phase 4
- RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER TrialCompletedNCT02303795Phase 2
- A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance HemodialysisCompletedNCT02289703Phase 1
- Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee ArthroplastyCompletedNCT02271399Phase 2
- Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation TrialCompletedNCT02168829Phase 4
- Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulationCompletedNCT02161965Phase 4
- Rivaroxaban in Thrombotic Antiphospholipid SyndromeTerminatedNCT02157272Phase 3
- Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.TerminatedNCT02128841Phase 2
- Rivaroxaban Anticoagulation for Superficial Vein ThrombosisCompletedNCT02123524Phase 3
- Rivaroxaban for Antiphospholipid Antibody SyndromeCompletedNCT02116036Phase 4
- Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.Status unknownNCT02085824Not applicable
- Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass SurgeryTerminatedNCT02058199Phase 1
- Evaluation of Wound Drainage After Knee or Hip ArthroplastyWithdrawnNCT02054936Phase 4
- Dose-finding of Rivaroxaban in HemodialysisCompletedNCT02047006Phase 4
- Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With CancerCompletedNCT01989845Phase 4
- Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) StudyStatus unknownNCT01986192Not applicable
- A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy VolunteersCompletedNCT01954238Phase 1
- Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular EventsStatus unknownNCT01923818Phase 2/3
- Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard TabletCompletedNCT01853800Phase 1
- Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial FlutterCompletedNCT01839357Phase 3
- Antithrombotic Triple Therapy in HumansCompletedNCT01812200Phase 4
- Anticoagulation With Rivaroxaban in Cardioversion -The ARC StudyCompletedNCT01747746Phase 4
- Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee ArthroplastyCompletedNCT01720108Phase 3
- Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)CompletedNCT01708850Phase 4
- Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic EventsCompletedNCT01675076Phase 3
- Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced ThrombocytopeniaTerminatedNCT01598168Phase 3
- Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) PatientsCompletedNCT01516840Phase 3
- Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) PatientsCompletedNCT01516814Phase 3
- Reversal of the Antithrombotic Action of New Oral AnticoagulantsStatus unknownNCT01478282Phase 4
- Pharmacokinetics Study of Oral Rivaroxaban in Healthy ParticipantsCompletedNCT01464450Phase 1
- Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary InterventionCompletedNCT01442792Phase 2
- Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty SurgeryCompletedNCT01431456Phase 3
- A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy VolunteersCompletedNCT01400646Phase 1
- A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)CompletedNCT01379300Phase 1
- A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney FunctionCompletedNCT01309438Phase 1
- Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thromboticsCompletedNCT01210755Phase 4
- Dose-confirmatory Bridging Study in Total Knee ReplacementCompletedNCT01206972Phase 3
- Dose-confirmatory Bridging Study in Total Hip ReplacementCompletedNCT01205932Phase 3
- Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric SubjectsCompletedNCT01145859Phase 1
- BAY59-7939 Japanese in Atrial Fibrillation (2nd)CompletedNCT00973323Phase 2
- BAY59-7939 in Atrial Fibrillation Once Daily (OD)CompletedNCT00973245Phase 2
- ODiXahip - a Phase IIa Dose Escalating Proof of Principle TrialCompletedNCT00839826Phase 2
- Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)CompletedNCT00839163Phase 2
- BAY59-7939, Japanese Phase II in Atrial FibrillationTrial StatusCompletedNCT00779064Phase 2
- An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging StudyCompletedNCT00402467Phase 2
- Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip ReplacementCompletedNCT00398905Phase 2
- Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip ReplacementCompletedNCT00396786Phase 2
- Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein ThrombosisCompletedNCT00395772Phase 2